GLP-1 Drugs Linked to Muscle Loss, Researchers Urge Physical Activity to Mitigate Risk
Patients taking GLP-1 receptor agonists, a class of medications used for weight management and diabetes, may experience both fat and lean muscle mass loss, according to a 2024 study published in *JAMA Internal Medicine*. Researchers emphasize that incorporating physical activity is critical to preserving muscle mass while on these drugs, which include semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda).
Why Muscle Loss Occurs on GLP-1 Drugs
GLP-1 drugs work by slowing gastric emptying, reducing appetite, and increasing insulin secretion. While effective for weight loss, they can lead to unintended muscle atrophy, particularly in individuals with low baseline physical activity. A 2023 review in *The Lancet Diabetes & Endocrinology* found that up to 15% of patients on GLP-1 therapies reported significant lean body mass reduction, with higher risks among older adults and those with sedentary lifestyles.
Physical Activity as a Countermeasure
The *JAMA* study recommends resistance training and moderate aerobic exercise to offset muscle loss. “Patients on GLP-1 drugs should engage in at least 150 minutes of weekly physical activity, including strength training sessions three times a week,” said Dr. Emily Carter, a clinical endocrinologist at the University of Michigan Health System. “This helps maintain metabolic health and prevents frailty.”
Blood Pressure Medications and Dizziness: A Separate Concern
While GLP-1 drugs target weight and glucose, another study in *Hypertension* highlighted risks for patients on blood pressure medications. Certain antihypertensives, including beta-blockers and diuretics, can cause dizziness or orthostatic hypotension, particularly when combined with weight loss from GLP-1 therapies. “The combination may increase fall risk, especially in older adults,” noted Dr. Michael Torres, a pharmacology expert at the Mayo Clinic.
What Patients Should Know
Healthcare providers are advised to monitor muscle mass and blood pressure regularly in patients on these medications. The American Diabetes Association (ADA) updated its guidelines in 2024 to include structured exercise prescriptions for GLP-1 users. “It’s not just about losing weight—it’s about preserving functional capacity,” said ADA spokesperson Dr. Lisa Nguyen.
Expert Recommendations for Safe Use
– For GLP-1 Users: Pair medication with resistance training (e.g., weightlifting, bodyweight exercises) and aerobic activities (e.g., walking, cycling).
– For Blood Pressure Patients: Avoid abrupt dose changes and report dizziness to a physician.
– General Advice: Consult a healthcare provider before starting any new exercise regimen, especially with preexisting conditions.
For more information, visit the American Diabetes Association or American Heart Association.